Business Context and Reporting Period
This Form 8-K is a current report filed by Oncocyte Corporation (trading symbol: OCX) on March 2, 2023, covering events occurring on February 24, 2023. The filing addresses significant changes in corporate leadership and governance.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on executive appointments and does not contain financial performance data.
Material Changes
- Executive Appointment: Joshua Riggs was appointed Chief Executive Officer (CEO) effective February 24, 2023.
- Additional Roles: Mr. Riggs was appointed President and joined the Board of Directors effective February 28, 2023.
- Background: Mr. Riggs had served as Interim CEO since December 2022. His compensation was previously disclosed in an 8-K filed on December 5, 2022.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or management commentary regarding future performance. No risks, contingencies, or unusual items were disclosed in this specific report. The document notes that no transactions requiring disclosure under Item 404(a) of Regulation S-K exist, and no family relationships exist between Mr. Riggs and other directors or officers.
Investor Verification Checklist
- Verify the press release dated March 2, 2023 (Exhibit 99.1) for full details on the leadership transition.
- Review the Form 8-K filed on December 5, 2022, to confirm the compensation package for Joshua Riggs.
- Confirm the effective dates of Mr. Riggs' roles: CEO (Feb 24, 2023) and Board Member/President (Feb 28, 2023).